Next Article in Journal
Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
Previous Article in Journal
Protein-Based Blood Substitutes: Recent Attempts at Controlling Pro-Oxidant Reactivity with and Beyond Hemoglobin
Previous Article in Special Issue
FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver
Open AccessReview

New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

Clinical Research Laboratory, Dept. of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen, Calwerstr. 7/1, 72076 Tuebingen, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(7), 881-914; https://doi.org/10.3390/ph6070881
Received: 29 March 2013 / Revised: 15 June 2013 / Accepted: 11 July 2013 / Published: 19 July 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future. View Full-Text
Keywords: RNAi; siRNA; ASO; transfection tools; delivery systems; atherosclerosis; CVD (cardiovascular disease); restenosis; drug eluting stents RNAi; siRNA; ASO; transfection tools; delivery systems; atherosclerosis; CVD (cardiovascular disease); restenosis; drug eluting stents
Show Figures

Figure 1

MDPI and ACS Style

Koenig, O.; Walker, T.; Perle, N.; Zech, A.; Neumann, B.; Schlensak, C.; Wendel, H.-P.; Nolte, A. New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases. Pharmaceuticals 2013, 6, 881-914.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop